Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression

被引：0
|
作者：
Li, Yunfeng [1 ]
Hu, Maitao [1 ]
Li, Lei [2 ]
Liu, Sheng [1 ]
He, Tingting [3 ]
Cheng, Chunyan [3 ]
Xu, Mian [3 ]
Yin, Xinmin [1 ]
机构：
[1] Hunan Normal Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, 61 Jiefang West Rd, Changsha, Peoples R China
[2] Shandong Univ, Dept Hepatobiliary Surg, Shandong Canc Hosp, Shandong Acad Med Sci, Jinan, Shandong, Peoples R China
[3] OrigiMed, Shanghai, Peoples R China
来源：
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY | 2021年 / 45卷 / 01期
关键词：
GUIDELINES; DIAGNOSIS;
D O I：
10.1016/j.clinre.2020.08.004
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL)
    Sumrall, Ashley
    Phuphanich, Surasak
    Spetzler, David
    Gatalica, Zoran
    Xiu, Joanne
    Provenzano, Aaron
    Brenner, Andrew J.
    Subramaniam, Deepa
    Pandey, Majari
    Heimberger, Amy
    Kesari, Santosh
    Korn, W. Michael
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 240 - 241
  • [22] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74
  • [23] Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer
    Di Federico, Alessandro
    Alden, Stephanie Leigh
    Smithy, James William
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Wang, Xinan
    Lamberti, Giuseppe
    Pecci, Federica
    Gandhi, Malini Marion
    Spurr, Liam Flinn
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Macrocyclic Peptide Inhibitor of PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Kuska, Katarzyna
    Skalniak, Lukasz
    Grudnik, Przemyslaw
    Musielak, Bogdan
    Plewka, Jacek
    Kocik, Justyna
    Stec, Malgorzata
    Weglarczyk, Kazimierz
    Sala, Dominik
    Wladyka, Benedykt
    Siedlar, Maciej
    Holak, Tad A.
    Dubin, Grzegorz
    ADVANCED THERAPEUTICS, 2021, 4 (02)
  • [25] Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
    Rawangkan, Anchalee
    Wongsirisin, Pattama
    Namiki, Kozue
    Iida, Keisuke
    Kobayashi, Yasuhito
    Shimizu, Yoshihiko
    Fujiki, Hirota
    Suganuma, Masami
    MOLECULES, 2018, 23 (08)
  • [26] Loss of heterozygosity associates with PD-L1 expression and tumor mutational burden in high-grade endometrial tumors
    Mazina, Varvara
    Rueda, Bo
    Eisenhauer, Eric
    Bregar, Amy
    Philp, Lauren
    Watkins, Jaclyn
    Johnstone, Sarah
    Growdon, Whitfield
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S15 - S15
  • [27] Incidence of high tumor mutation burden (TMB) and PD-L1 positivity in breast cancers and potential response to immune checkpoint inhibitors (ICPIs)
    Sokol, Ethan
    Albacker, Lee
    Soyano, Aixa
    Parrondo, Ricardo
    Ernst, Brenda
    Gabriel, Emmanuel
    Frampton, Garrett
    Ross, Jeffrey
    Ali, Siraj
    Chung, Jon
    Chumsri, Saranya
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [29] Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas
    Iorgulescu, Bryan
    Touat, Mehdi
    Li, Yvonne
    Spurr, Liam
    Grant, Gareth
    Pisano, William
    Lim-Fat, Mary Jane
    Lee, Eudocia
    Nayak, Lakshmi
    Chiocca, E.
    Huang, Raymond
    Cherniack, Andrew
    Wen, Patrick
    Idbaih, Ahmed
    Bielle, Franck
    Reardon, David
    Ligon, Keith
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy
    Hu, Weixian
    THORACIC CANCER, 2020, 11 (01) : 3 - 5
12345